Importantly, CML cells maintain a survival advantage by suppressing BIM transcription and by targeting BIM for proteasomal degradation through MAPK1-dependent phosphorylation [11–13]. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.